Geneva, Aug. 31 -- International Clinical Trials Registry received information related to the study (NCT07778940) titled 'Thiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI' on Aug. 19.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Tianjin Medical University Cancer Institute and Hospital
Condition:
Leptomeningeal Metastasis
Intervention:
Drug: Thiotepa
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 2026
Target Sample Size: 50
Countries of Recruitment:
China
To know more, visit htt...